The Cancer Gene Census (CGC) is a widely used module within the Catalogue Of Somatic Mutations In Cancer (COSMIC) that comprises an ongoing effort to catalogue and describe all genes with causal impact in human cancer. In CGC, genes are characterized according to their roles in cancer – tumor suppressor, oncogene or fusion gene – and divided into two tiers based on the strength of supporting evidence. On

October 15, our COSMIC and QIAGEN field applications experts will walk you through the scientific and curation processes behind CGC. We will also explore another module, the Cancer Mutation Census (CMC), which classifies coding variants according to their computed pathogenicity. This helps prioritize variants by highlighting mutations with proven functional or clinical relevance, supporting faster interpretation and decision-making.

You will learn about:

• The criteria used to evaluate genes for inclusion into the CGC

• The structured information captured within the CGC and CMC modules

• Their real-world applications across research and clinical contexts

Speaker Info: 

• Ellen Wiedemann is an Application Scientist at the Welcome Sanger Institute with over a decade of experience in next-generation sequencing (NGS) and bioinformatics.

• Kyle Nilson, PhD is a sequencing-focused molecular biologist with a background in biochemistry and technical support. As a field software trainer at QIAGEN Digital Insights, Dr. Nilson works closely with our global bioinformatics team to provide direct customer support and assist with software training, implementation and optimization.